Electrochemical sensor for doping corticosteroids in sports / Sensor eletroquímico para corticosteróides dopantes nos esportes / Sensor electroquímico para el dopaje de corticoesteroides en los deportes

ABSTRACT Introduction: Identifying and measuring the concentration of Triamcinolone (TA) in biological fluids is essential, especially for patients receiving intensive antibiotic medication. Objective: Make a sensor for electrochemical detection of Triamcinolone (TA) as an anabolic steroid in sports using copper oxide nanomaterials-reduced graphene oxide nanoparticles (CuNPs/rGO). Method: After preparing rGO nanoparticles on a glassy carbon electrode (GCE) using the modified Hummers technique, Cu NPs were deposited on rGO/GCE. The applicability of Cu NPs/rGO/GCE was investigated to determine the TA concentration in a real sample that had been prepared. Results: The deposited irregular Cu NPs evidenced a diameter of about 80 nm, in agreement with SEM morphological investigations. Amperometric studies revealed that the linear range, detection limits, and sensitivity of CuNPs/rGO/GCE as a TA sensor were 10 to 80 µM, 10nM, and 0.06584 µA/µM, respectively. Conclusion: The results revealed that the RSD and recovery values were valid, providing adequate quality and reliability for practical analysis of real samples using Cu NPS/rGO/GCE. Level of evidence II; Therapeutic studies - investigation of treatment outcomes.

RESUMO Introdução: É essencial identificar e medir a concentração de triamcinolona (TA) em fluidos biológicos, especialmente para pacientes que recebem medicação antibiótica intensiva. Objetivo: Confeccionar um sensor para detecção eletroquímica da triamcinolona como esteróides anabolizantes em esportes utilizando nanomateriais de óxido de cobre-nanopartículas de óxido de grafite reduzido (CuNPs/rGO). Métodos: Após a elaboração das nanopartículas rGO em eletrodo de carbono vítreo (GCE) utilizando a técnica Hummers modificada, os NPs Cu foram depositados no rGO/GCE. A fim de determinar a concentração de TA em uma amostra real que tinha sido preparada, foi investigada a aplicabilidade de Cu NPs/rGO/GCE. Resultados: Os Cu NPs irregulares depositados evidenciaram um diâmetro de cerca de 80 nm, de acordo com as investigações morfológicas do SEM. Estudos de amperometria revelaram que a faixa linear, limites de detecção e sensibilidade do CuNPs/rGO/GCE como sensor TA foram de 10 a 80 µM, 10nM e 0,06584 µA/µM, respectivamente. Conclusão: Os resultados revelaram que os valores de RSD e recuperação eram válidas, fornecendo qualidade e confiabilidade adequadas para análises práticas de amostras reais usando Cu NPs/rGO/GCE. Nível de evidência II; Estudos terapêuticos - investigação dos resultados de tratamento.

RESUMEN Introducción: Es esencial identificar y medir la concentración de triamcinolona (TA) en los fluidos biológicos, especialmente en los pacientes que reciben medicación antibiótica intensiva. Objetivo: Fabricar un sensor para la detección electroquímica de triamcinolona como esteroides anabólicos en el deporte utilizando nanomateriales de óxido de cobre-nanopartículas de óxido de grafeno reducido (CuNPs/rGO). Método: Tras la preparación de las nanopartículas de rGO sobre el electrodo de carbono vítreo (GCE) utilizando la técnica de Hummers modificada, se depositaron los NPs de Cu sobre el rGO/GCE. Para determinar la concentración de TA en una muestra real que había sido preparada, se investigó la aplicabilidad de los NPs de Cu/rGO/GCE. Resultados: Los NPs de Cu irregulares depositados presentaban un diámetro de unos 80 nm, de acuerdo con las investigaciones morfológicas del SEM. Los estudios amperométricos revelaron que el rango lineal, los límites de detección y la sensibilidad de Cu NPs/rGO/GCE como sensor de TA era de 10 a 80 µM, 10nM y 0,06584 µA/µM, respectivamente. Conclusión: Los resultados revelaron que los valores de RSD y recuperación eran válidos, proporcionando una calidad y fiabilidad adecuadas para el análisis práctico de muestras reales utilizando Cu NPs/rGO/GCE. Nivel de evidencia II; Estudios terapéuticos - investigación de los resultados del tratamiento.

Tratamiento de la eritrodisestesia palmoplantar con una fórmula magistral de urea 20% + triamcinolona acetónido 0, 2% + lidocaína 2% / Treatment of palmoplantar erythrodysesthesia with a compounding of urea 20% + triamcinolone acetonide 0.2% + lidocaine 2%

La eritrodisestesia palmoplantar es una reacción adversa cútanea secundaria al tratamiento quimioterápico y relativamente frecuente. Cursa con enrojecimiento, hinchazón, ardor y sensibilidad; en los casos más graves produce descamación de la piel, ampollas y dolor intenso afectando a la deambulación y calidad de vida de los pacientes.Se presenta el caso de una mujer a tratamiento con capecitabina que en el tercer ciclo de tratamiento presenta eritrodisestesia palmoplantar con empeoramiento en el octavo ciclo. El Servicio de Dermatología solicita al Servicio de Farmacia la elaboración de una crema de alantoína 6%. Desde el Servicio de Farmacia se propone la adición de un corticoide por sus propiedades inflamatorias y un anestésico para alivio del dolor. A los 7 días de inicio de tratamiento la paciente describe una leve mejoría, pero continúa con descamación en los pies; por lo que el Servicio de Farmacia propone cambio de alantoína por urea e incorporar un corticoide más potente. Se mantiene la lidocaína y se cambia la base de O/W a W/O para favorecer la penetración de los fármacos en la zona palmar y plantar.La composición final de la fórmula magistral es (100 g): urea 20 g, lidocaína 2 g, acetónido de triamcinolona 0,2 g, glicerina 3 g, alantoína 1 g, aceite de argán 5 g, vaselina filante 9 g, agua conservante 35 ml y base de absorción PR W/O 25 g.Tras 45 días de tratamiento con la fórmula propuesta, la paciente presenta muy buena evolución y mejoría desde el punto de vista sintomático. Además, ha mejorado notablemente la deambulación haciendo vida normal. (AU)

Palmoplantar erythrodysesthesia is a relatively frequent adverse cutaneous reaction secondary to chemotherapy treatment. It produces redness, swelling, burning and sensitivity. In the most severe cases it produces skin desquamation, blisters and intense pain affecting patients’ ambulation and quality of life.We present the case of a woman on a capecitabine treatment who during the third cycle of treatment presents palmoplantar erythrodysesthesia, worsening during the eighth cycle. The Dermatology Department requested the Pharmacy Department the elaboration of a 6% allantoin cream. The Pharmacy Department proposes the addition of a corticosteroid, due to its anti-inflammatory properties, and the addition of an anesthetic for pain relief. 7 days after having started the treatment, the patient describes a slight improvement, but she still presents feet desquamation. Therefore, the Pharmacy Department proposed changing allantoin for urea and introducing a stronger corticosteroid. Lidocaine is maintained and the base is changed from O/W to W/O to favor the penetration of the drugs in the palmar and plantar areas.The final composition of the compounding is (100 g): urea 20 g, lidocaine 2 g, triamcinolone acetonide 0.2 g, glycerin 3 g, allantoin 1 g, argan oil 5 g, stringy vaseline 9 g, preservative water 35 mL and PR W/O absorption base 25 g.Afer 45 days of treatment with the proposed compounding, the patient shows a very good evolution and improvement from the symptomatic point of view. Moreover, she has significantly improved the ambulation and can return to normal life. (AU)

Choroidopathy and optic neuropathy in systemic lupus erythematosus, a case report.

Although the associated ocular pathology to systemic lupus erythematosus is not infrequent, its manifestations and importance can be overlooked by rheumatologists and ophthalmologists. We present the case of a 44-year-old male with a history of systemic lupus erythematosus whose disease started with metamorphopsia and subjective alteration of the visual fields of both eyes, with a marked decrease in visual acuity, secondary to bilateral serous retinal detachment and optic neuropathy. He received systemic corticosteroids, biological therapy and posterior subtenon triamcinolone acetonide injections, showing an improvement in visual acuity. Ophthalmic manifestations should be considered a sign of systemic lupus erythematosus activity, therefore the treatment is essentially systemic, in combinationed with local coadjutant treatment.

Coroidopatía y neuropatía óptica en lupus eritematoso sistémico, reporte de caso / Choroidopathy and optic neuropathy in systemic lupus erythematosus, a case report

Si bien la patología ocular asociada a lupus eritematoso sistémico no es infrecuente, sus manifestaciones e importancia pueden ser a veces pasadas por alto por reumatólogos y oftalmólogos. Se describe el caso de un varón de 44 años con antecedente de lupus eritematoso sistémico que inicia enfermedad con metamorfopsias y alteración subjetiva de campos visuales de ambos ojos, presentando disminución marcada de agudeza visual secundaria a desprendimiento de retina seroso bilateral y neuropatía óptica. Recibió tratamiento con corticoides sistémicos, terapia biológica e inyecciones subtenonianas posteriores de triamcinolona, presentando mejoría de la agudeza visual. Las manifestaciones oftálmicas deben ser consideradas como signo de actividad del lupus eritematoso sistémico, por ese motivo el tratamiento es esencialmente sistémico, asociado a tratamiento coadyuvante local.

Although the associated ocular pathology to systemic lupus erythematosus is not infrequent, its manifestations and importance can be overlooked by rheumatologists and ophthalmologists. We present the case of a 44-year-old male with a history of systemic lupus erythematosus whose disease started with metamorphopsia and subjective alteration of the visual fields of both eyes, with a marked decrease in visual acuity, secondary to bilateral serous retinal detachment and optic neuropathy. He received systemic corticosteroids, biological therapy and posterior subtenon triamcinolone acetonide injections, showing an improvement in visual acuity. Ophthalmic manifestations should be considered a sign of systemic lupus erythematosus activity, therefore the treatment is essentially systemic, in combinationed with local coadjutant treatment.

Potential effect of hyaluronic acid and triamcinolone acetate, alone or combined, on chondrogenic differentiation of mesenchymal stem cells / Efecto potencial del ácido hialurónico y del acetato de triamcinolona solos o combinados sobre la diferenciación condrogénica de células-tronco mesenquimales / Efeito potencial do ácido hialurônico e triancinolona acetonida, isolados e combinados, na diferenciação condrogênica de células-tronco mensenquimais

Abstract Background: Osteoarthritis is a complex degenerative disease with several factors contributing to joint damage. Objective: To compare the potential effect of hyaluronic acid (HA) and triamcinolone acetonide (TA), alone or combined, on the in vitro chondrogenic differentiation process of mesenchymal stem cells (MSCs). Methods: MSCs were divided into four groups: Control, HA, TA, and HA/TA combined. Each treatment group was cultured for 14 days in chondrogenic differentiation medium. The chondrogenic differentiation potential was assessed by histology and immunohistochemistry. Results: The HA and HA/TA-treated MSCs presented histological characteristics similar to native chondrocytes. The extracellular matrix (ECM) of TA-treated MSCs was compact and organized. Glycosaminoglycan staining was intense in Control, moderate in TA, slight in HA/TA, and undetectable in HA. Type II collagen immunoreactivity was high in the TA-treated ECM and MSCs. Conclusions: Histological analysis shows that HA influences morphological development similar to chondrocytes of the MSCs, but with low expression of specific cartilage molecules. The TA promotes formation of a compact and organized ECM.

Resumen Antecedentes: La osteoartritis es una enfermedad degenerativa compleja en la cual varios factores contribuyen al daño articular. Objetivo: Comparar el efecto del ácido hialurónico (HA) y acetónido de triamcinolona (TA), solos o en combinación, en el proceso de diferenciación condrogénica in vitro de células madre mesenquimales (MSCs). Métodos: Las MSCs fueron divididas en cuatro grupos: Control, HA, TA y HA/TA, y cultivadas por 14 días en medio de diferenciación condrogénica para cada tratamiento. El potencial de diferenciación condrogénica fue analizado por medio de histología e inmunohistoquímica. Resultados: Las MSCs tratadas con HA y HA/TA, presentaron características histológicas similares a los condrocitos nativos, y la matriz extracelular (ECM) de MSCs tratadas con TA fue más compacta y organizada. La tinción de glicosaminoglicanos fue intensa en el Control, moderada en TA, ligera en HA/TA, y sin tinción en HA. La inmunoreactividad para colágeno tipo II fue más alta en las MSCs y ECM tratadas con TA. Conclusión: El análisis histológico muestra que el HA influencia un desarrollo morfológico similar a los condrocitos de las MSCs, pero con baja expresión de moléculas específicas de cartílago. La TA promueve la formación de una ECM compacta y organizada.

Resumo Antecedentes: A osteoartrite é uma doença degenerativa complexa, na qual vários fatores contribuem ao dano articular. Objetivo: Comparar o efeito do ácido hialurônico (HA) e Triancinolona acetonida (TA), só ou combinado no processo de diferenciação condrogênica in vitro de células tronco mesenquimais (MSCs). Métodos: MSCs foram divididas em 4 grupos: Controle, HA, TA y HA/TA e cultivadas por 14 dias com meio de diferenciação condrogênica e seus respectivos tratamentos. O potencial de diferenciação condrogênica foi acessado por meio de histologia e imunohistoquímica. Resultados: Histologicamente, MSCs tratadas com HA e HA/TA apresentaram características semelhantes de condrócitos nativos, e a matriz extracelular de MSCs tratadas com TA foi mais compacta e organizada. A coloração para glicosaminoglicanos foi intensa no Controle, moderada no TA, leve no HA/TA e sem coloração com HA. Para os grupos tratamento, a imunoreatividade para colágeno tipo II foi maior nas células e matriz extracelular tratadas com TA. Conclusão: Mediante análise histológica, o HA influenciou o desenvolvimento morfológico semelhante a condrócitos das MSCs, mas com baixa expressão de moléculas específicas de cartilagem. A TA promoveu a formação de uma matriz extracelular compacta e organizada.

Rehabilitación de trauma facial ocasionado por fuegos artificiales utilizando triamcinolona / Aesthetic and functional rehabilitation using triamcinolone on patient suffered by facial firework injury

Introduction: Facial injuries are a common occurrence at the emergency room. Treatment for this type of trauma is complex in terms of re-establishing good oral and facial function, plus aesthetics. Objective: This paper aims to report a clinical case of aesthetic and functional rehabilitation using triamcinolone in a patient affected on the face by a fireworks explosion. Case report: A 26-year-old man was admitted to the oral and maxillofacial surgery service of the Sergipe Urgency Hospital presenting trauma after the explosion of a "Firework rocket" in his face. The patient had extensive soft tissue injury in gingival mucosa, right labial commissure, and tongue. There was also inferior incisive avulsion and dentoalveolar fracture. His clinical and tomographic evaluation presented comminuted mandibular fracture. After eighteen days he was discharged and sent to the dentistry service of the Federal University of Sergipe for aesthetic and functional rehabilitation of his facial damages. Two months later, the patient attended a University dental service to begin aesthetic and postoperative functional rehabilitation. First, the necrotic bone was removed, following intralesional infiltration of hexacetonide triamcinolone 20mg/mL into the scar of the labial region and the commissure of the lips was performed. Each application was performed after twenty days of interval. Later, lingual frenectomy and glossosplasty were done for improving his lingual mobility and then hexacetonide triamcinolone 20mg/mL infiltrations were also done in the tongue base in the following sessions. Conclusions: After five infiltrations, it was observed an improvement in the scar appearance and texture, which also had a lower contracture, as well as a lingual motricity improvement(AU)

Introducción: Las lesiones faciales son frecuentes en el servicio de emergencia. El tratamiento para este tipo de trauma es complejo en términos de restablecer una buena función bucal y facial, además de la estética. Objetivo: Reportar un caso clínico de rehabilitación estética y funcional a través del uso de hexacetónido de triamcinolona en un paciente afectado por una explosión de fuegos artificiales en su rostro. Caso clínico: Hombre de 26 años ingresado en el servicio de cirugía oral y maxilofacial del Hospital de Urgencia de Sergipe por presentar un traumatismo después de la explosión contra su rostro de un cohete de fuegos artificiales. El paciente tenía una lesión extensa de partes blandas en la mucosa gingival, comisura labial derecha y lengua. También hubo avulsión incisiva inferior y fractura dentoalveolar. A través de la evaluación clínica y de tomografía, fue posible observar fragmentación múltiple ósea en el sitio de la fractura, compatible con fractura mandibular conminuta. Después de dieciocho días fue dado de alta y enviado al servicio de odontología de la Universidad Federal de Sergipe para la rehabilitación estética y funcional de sus daños faciales. Dos meses después, el paciente asistió al servicio dental de la universidad para comenzar la rehabilitación funcional estética y posoperatoria. Primero, se retiró el hueso necrótico, luego se realizó la infiltración intralesional de hexacetónido de triamcinolona 20 mg/mL en la cicatriz de la región labial y se realizó la comisura de los labios; con un intervalo de 20 días entre cada aplicación. Posteriormente, se realizaron frenectomía lingual y glososplastia, para mejorar su movilidad lingual, y luego se realizaron infiltraciones de 20 mg/mL de hexacetónido de triamcinolona en la base de la lengua en las sesiones siguientes. Comentarios principales: Después de cinco infiltraciones se observó una mejora en el aspecto y la textura de la cicatriz, que también tenía una contractura más baja, así como una mejora de la motricidad lingual(AU)

Inyección intralesional de corticoesteroides como tratamiento conservador del granuloma central de células gigantes: revisión de la literatura / Intralesional corticosteroid injection as a conservative treatment for central giant cell granuloma: a review of the literature

El granuloma central de células gigantes (GCCG) es una lesión benigna intraósea de los maxilares. Tradicionalmente, la cirugía es el tratamiento más utilizado para este tipo de patología, sin embargo, en los últimos años se ha propuesto el uso de inyecciones intra- lesionales de corticoesteroides como alternativa conservadora. El objetivo de este estudio fue realizar una revisión bibliográfica de los casos tratados con corticoesteroides. Para esto, se utilizó la plataforma de PubMed y Google Scholar para buscar artículos publica- dos entre 1994 y el 2020, relacionados al GCCG y su tratamiento con corticoesteroides. Se encontraron 28 artículos y un resumen con 61 pacientes en total; en la mayoría de los casos se utilizaron inyecciones intralesionales semanales de acetonido de triamcinolona con anestésico durante 6 semanas, aunque se reportaron variantes del protocolo. De los 61 casos, 38 tuvieron una resolución completa y en los demás casos fue necesario realizar tratamiento quirúrgico adicional. Con base en lo anterior, parece que el uso de inyecciones intralesionales de triamcinolona tiene un efecto positivo en el tratamiento del GCCG al permitir una resolución completa de la lesión o una disminución en su tamaño, de manera que la cirugía posterior sea más conservadora.

Central giant cell granuloma (CGCG) is a benign intraosseous lesion of the jaws. Traditionally, surgery is the most used treatment for this type of pathology, however, in recent years the use of intralesional corticosteroids injections has been proposed as a conservative alternative. The aim of this study is to carry out a bibliographic review of the cases treated with corticosteroids. The author used PubMed and Google Scholar platforms were used to search for articles published between 1994 and 2020, related to CGCG and its treatment with corticosteroids. The results of this research were 28 articles and one abstract were found with 61 patients in total; in most cases, weekly intralesional injections of triamcinolone acetonide with anesthetic were used for 6 weeks, although protocol variants were reported. Of the 61 cases, 38 had complete resolution while the other cases required additional surgical treatment. From this, it seems that the use of intralesional triamcinolone injections have a positive effect in the treatment of CGCG by allowing a complete resolution of the lesion or a decrease in its size, so that subsequent surgery is more conservative.

Buena respuesta a tratamiento con triamcinolona en Sarcoidosis Cutánea / Good response to treatment with triamcinolone in Cutaneous Sarcoidosis

RESUMEN La sarcoidosis es una enfermedad granulomatosa multisistémica, de etiología desconocida y evolución crónicaque afecta con mayor frecuencia los pulmones, los ojos y la piel. Aproximadamente un 25% de los pacientes presentan como única manifestación la forma cutánea. Se presenta el caso clínico de una paciente con diagnósticode sarcoidosis cutánea, a quien se le realizó tratamiento con infiltraciones de triamcinolona obteniendo muy buena respuesta. Se realiza unarevisión de la literatura.

ABSTRACT Sarcoidosis is a multisystemic granulomatous disease of unknown etiology with chronic evolution the most frequently affectes the lungs, eyes and skin. Approximately 25% of patients present as the only manifestation the cutaneous form. We present the clinical case of a patient diagnosed with cutaneous sarcoidosis, who underwent treatment with triamcinolone infiltrations, obtaining a very good response. Areview of the literatureisalso carried out.

Uso terapéutico de la hialuronidasa y la triamcinolona en el pseudotumor orbitario / Therapeutic use of hyaluronidase and triamcinolone in orbital pseudotumor

RESUMEN El origen del pseudotumor orbitario no es del todo conocido. Se admite su naturaleza inflamatoria granulomatosa e inespecífica en diferentes localizaciones. El pseudotumor orbitario se define como una respuesta inflamatoria celular pleomórfica, que está usualmente confinado a estructuras de la órbita y tiene una evolución limitada. En este trabajo se presenta una paciente femenina de 16 años, con diagnóstico de pseudotumor orbitario corroborado por biopsia y tomografía axial computarizada, refractaria al tratamiento con esteroides sistémicos, por lo que se decide iniciar con la aplicación de hialuronidasa y triamcinolona en el espacio peribulbar. Los casos agudos casi siempre responden rápidamente al tratamiento con cortocoesteroides, como prednisona, pero debemos tener en cuenta que existen pacientes que son refractarios al tratamiento, por lo que es necesario buscar procedimientos alternativos. Una opción es el uso de hialuronidasa para destruir las uniones extracelulares, y difundir un esteroide de manera local, como la triamcinolona, más efectiva dentro del tejido inflamatorio para provocar un efecto localizado de este. A los tres meses del tratamiento hubo una regresión total del cuadro en esta paciente(AU)

ABSTRACT The exact etiology of orbital pseudotumor is unknown, but its granulomatous unspecific inflammatory nature at various locations has been recognized. Orbital pseudotumor is defined as a cellular pleomorphic inflammatory response of limited evolution often confined to orbital structures. A case is presented of a female 16-year-old patient diagnosed with orbital pseudotumor confirmed by biopsy and computerized axial tomography, refractory to treatment with systemic steroids, due to which it is decided to start treatment with hyaluronidase and triamcinolone in the peribulbar space. Acute cases often respond fast to treatment with corticosteroids such as prednisone. It should be borne in mind that there are patients who are refractory to treatment for whom alternative treatments should be sought. An option is the use of hyaluronidase to destroy extracellular junctions and locally spread a steroid such as triamcinolone, most effectively within the inflammatory tissue to ensure its localized effect. Total regression of the patient's status was observed at three months of treatment(AU)

Cicatriz queloide gigante / Giant keloid scar

Introducción: La cicatriz queloide forma parte de las cicatrices patológicas por exceso; es una afección que se caracteriza por el depósito excesivo de colágeno en la dermis y tejido celular subcutáneo. El proceso por el cual se desarrolla no es del todo conocido, es más frecuente en la raza negra y afecta en igual proporción a hombres que mujeres. Objetivo: Informar a la comunidad médica sobre experiencia en el manejo y tratamiento con dos pacientes portadores de lesiones queloides de gran tamaño. Caso clínico: Se presentan dos pacientes con cicatriz queloide gigante a partir de ambos lóbulos auriculares y cuello anterior; se expone la conducta terapéutica basada en la combinación de tres modalidades de tratamiento: cirugía; infiltración con acetónido de triamcinolona, 1 ml (40 mg) desde el día del acto quirúrgico, se repitió cada 15 días; junto a presoterapia con crema esteroidea. Conclusiones: Aunque no existe un tratamiento ideal, se debe tener en cuenta al tratar esta enfermedad si se está ante una lesión recidivante, el tiempo de aparición de la tumoración, sus características clínicas; de seleccionarse el tratamiento quirúrgico como opción terapéutica, debe acompañarse de otras modalidades de tratamiento(AU)

Introduction: The keloid scar is part of the pathological scars by excess, is a condition characterized by the excessive deposit of collagen in the dermis and subcutaneous cell tissue, the process by which it develops is not entirely known, it is more frequent in the black race, affects in equal proportion men than women. Objective: To inform the medical community of the experience in handling and treating two patients with large keloid lesions. Clinical case: Two patients with giant keloid scars are presented from both earlobes and anterior neck where therapeutic behavior based on the combination of three treatment modalities is exposed: surgery, triamcinolone acetonide 1 ml (40mg) infiltration beginning on the first day after surgery, repeated every 15 days and pressotherapy with steroid cream. Conclusions: Although there is no ideal treatment, it should be taken into account when treating this disease if we are facing a recurrent injury, the time of onset of the tumor, its clinical characteristics, surgical treatment should be selected as a therapeutic option, accompanied by other forms of treatment(AU)

Bilateral and multifocal central serous chorioretinopathy after injecting triamcinolone into a chalazion. / Coriorretinopatía serosa central bilateral y multifocal después de inyectar triamcinolona en un chalazión.

We present a case of bilateral and multifocal central serous chorioretinopathy that developed one month after an intra-chalazion triamcinolone acetonide injection. Central serous chorioretinopathy spontaneously resolved during observation 3 months after diagnosis. We believe that central serous chorioretinopathy can occur as a complication of administration of depot corticosteroids even at a low dose.

Immune recovery uveitis in a patient with herpes retinitis as a complication of hairy cell leukaemia. / Respuesta similar a la uveítis de recuperación inmune en un paciente con retinitis herpética como complicación de una leucemia de células peludas.

A 51 year-old man with hairy cell leukaemia was treated with pentostatin. While receiving the treatment, he was diagnosed with herpes retinitis in his right eye. After the last cycle of pentostatin the patient developed a mild vitritis and cystoid macular oedema. There were no signs of herpes retinitis reactivation. After excluding other possible causes of intraocular inflammation, a diagnosis of immune recovery uveitis was made. The patient was treated with 2-monthly retro-septal injections of triamcinolone, oral corticosteroids, intravitreal dexamethasone implants and, finally, pars plana vitrectomy. An immune recovery uveitis-like response is possible in HIV negative individuals. The immune reconstitution after the treatment of hairy cell leukaemia may have led to intraocular inflammation. Management of immune recovery uveitis is challenging and difficult. Pars plana vitrectomy may be necessary. Ophthalmologists should be alert to the possibility of immune recovery uveitis in HIV negative patients.

Efecto antiangiogénico de la triamcinolona asociada a lidocaína con epinefrina de uso odontológico en la membrana alantocoriónica de pollo / Antiangiogenic effect of triamcinolone associated with lidocaine with epinephrine for dental use in chicken chorioallantoic membrane

RESUMEN: El proceso angiogénico se define como el proceso en el que los vasos sanguíneos generan brotes dando como resultado neovascularidad. Un desbalance en el proceso angiogénico contribuye a numerosos desórdenes inflamatorios, infecciosos, isquémicos, inmunológicos y malignos. En el territorio maxilofacial se pueden encontrar patologías neoplásicas benignas de desarrollo local con un marcado componente angiogénico que determinan su crecimiento y agresividad. Sin embargo, existe escasa evidencia de cómo tratarlas en base al control de la angiogénesis. Terry & Jacoway (1994) desarrollaron un protocolo de tratamiento para lesiones neoplásicas benignas con un importante componente vascular que se utiliza actualmente. Este protocolo consiste en la infiltración intralesional de una suspensión de triamcinolona 10 mg/ml más una solución de anestésico local de uso odontológico como la lidocaína al 2 % asociada a epinefrina en una concentración de 1:200.000. Sin embargo, el uso de epinefrina podría disminuir la acción antiangiogénica de la triamcinolona al ser un vasoconstrictor. El objetivo de este estudio es comparar el efecto antiangiogénico, en la membrana alantocoriónica de pollo (MAC), de esta suspensión versus el efecto de la triamcinolona sin asociar a anestésicos locales. Los resultados del efecto antiangiogénico en la MAC de pollo, obtenidos en la investigación concluyeron que la suspensión de triamcinolona asociada a lidocaína con epinefrina es similar al de la suspensión de triamcinolona sin asociar a anestésicos locales. Además, se logró determinar que las suspensiones de triamcinolona sin asociar a anestésicos locales y las asociadas a anestésicos locales con o sin vasoconstrictor poseen un marcado efecto antiangiogénico, en la MAC de pollo, en comparación al grupo control.

SUMMARY: Angiogenesis is defined as the process through which new blood vessels form from previously existing vessels. Several inflammatory, infectious, ischemic, immunological and malignant disorders are caused by the lack of adequate angiogenesis balance. In the maxillofacial area, there are invasive benign neoplastic pathologies with a strong angiogenic component, which determines aggressive behavior and growth. Studies in the literature are scarce regarding treatment of these conditions based on angiogenesis control. Currently, the protocol used to treat these maxillofacial benign neoplastic lesions, was developed in 1994 by Terry & Jacoway and has a strong angiogenic component. Consequently lesions are treated via intra-lesion administration of triamcinolone 10 mg / mL, a solution used in dental local anesthetic, such as lidocaine 2 %, in conjunction with epinephrine at a concentration of 1:200,000. The objective of this study was to compare the antiangiogenic effect of this protocol in chicken chorioallantoic membrane (CAM) without the use of local anesthetic. The results of the antiangiogenic effect in the CAM obtained in this study concluded that the effect of the suspension of triamcinolone associated to lidocaine with epinephrine, is similar to the suspension of triamcinolone without associating local anesthetics. Furthermore, it was determined that suspensions of triamcinolone without local anesthetic, and those associated to local anesthetic with, and without vasoconstrictor have a strong antiangiogenic effect in CAM compared to the control group.

Treatment of oral lichen planus. Systematic review and therapeutic guide. / Tratamiento del liquen plano oral. Revisión sistemática y protocolo de actuación.

In this systematic review, 55 structured articles on the therapeutic efficacy against pain and clinical signs of oral lichen planus (OLP) were analysed. The literature search was developed according to the criteria of the PRISMA system, selecting the tests performed using one of the following methodological designs: drug (active ingredient) vs. drug in different excipient or concentration, drug vs. different active principle, drug vs. phytotherapy and drug vs. treatment with phototherapy. Based on the results, an algorithm is proposed to guide the treatment of OLP in its atrophic and erosive clinical forms. The use of clobetasol propionate at 0.025-0.05% of topical application as the first therapeutic alternative is highlighted. Secondly, 0.1% tacrolimus and 1% pimecrolimus also formulated for its topical regimen. And finally, we address the use of systemic corticosteroids and the application of diode lasers.

Efecto de la dehidroepiandroesterona y el acetónido de triamcinolona sobre la línea celular 3T3-L1 / Effect of dehydroepiandroesterone and triamcinolone acetonide on 3T3-L1 cell line

RESUMEN: La piel es el órgano más extenso en el ser humano, su integridad representa protección contra diferentes agentes químicos, biológicos y mecánicos. Las lesiones ocasionadas en este tejido se resuelven mediante la formación de una cicatriz, sin embargo, diferentes alteraciones moleculares pueden sobre estimular este proceso, lo que conlleva a la formación de cicatrices aberrantes (hipertrófica o queloide). El tratamiento más recomendado para este tipo de lesiones es la aplicación intralesional del acetónido de triamcinolona (AT) y por otro lado, la dehidroepiandrosterona (DHEA) es una pro-hormona que posee una gran variedad de efectos biológicos como: regulación de la síntesis de fibras de colágeno, protección celular, propiedades antitumorales, antiinflamatorias y antioxidante. En este trabajo, se estudió la combinación de AT-DHEA sobre la proliferación y muerte celular en la línea celular de fibroblastos 3T3-L1. Los resultados mostraron que la AT a 100 M y la DHEA a 1000 M inhiben la proliferación en un 50 y 40% respectivamente. La combinación de AT-DHEA (10000-10 M) inhibe la proliferación celular e inducen muerte celular programada, entonces esta combinación pudiera utilizarse en cicatrices hipertróficas o queloides para su eliminación.

ABSTRACT: The skin in the human is the largest organ, his integrity represents protection against various chemical, biological and mechanical agents. The injuries in this tissue are solved by forming a scar, however, different molecular alterations may overstimulate this process, leading to the formation of aberrant scars (hypertrophic or keloid). The most recommended treatment for such injuries is the intralesional application of triamcinolone acetonide (TA) and on the other hand, dehydroepiandrosterone (DHEA) is a pro-hormone that has a wide variety of biological effects such as regulation of the synthesis of collagen fibers, cell protection, anti-tumor properties, anti-inflammatory and antioxidant. In this paper, the combination of AT-DHEA on proliferation and cell death in fibroblast cell line 3T3-L1 was studied. The results showed that the AT 100 and 1000 M DHEA to inhibit proliferation by 50 and 40% respectively. The combination of AT-DHEA (10000-10 M) inhibits cell proliferation and induce programmed cell death, so this combination could be used in hypertrophic or keloid scars for disposal.

Intra-articular injection with triamcinolone hexacetonide in patients with rheumatoid arthritis: prospective assessment of goniometry and joint inflammation parameters / Injeção intra-articular de hexacetonido de triancinolona em pacientes com artrite reumatoide: avaliação prospectiva da goniometria e parâmetros de inflamação articular

Abstract Objectives: To evaluate local joint variables after intra-articular injection with triamcinolone hexacetonide in rheumatoid arthritis patients. Methods: We blindly and prospectively (baseline, 1, 4, 12 and 24 weeks) evaluated metacarpophalangeal, wrist, elbow, shoulder, knee and ankle joints after triamcinolone hexacetonide intra-articular injection by the following outcome measures: visual analogue scale 0–10 cm (VAS) for rest pain (VASR); VAS for movement pain (VASM); VAS for joint swelling (VASSw); flexion (FlexG) and extension (ExtG). Results: 289 patients (635 joints) were studied. VASSw (p < 0.001) and VASR (0.001 < p < 0.016) improved from T0 to T4, T12 and T24 for all joints. VASM improved from T0 to T4 (p < 0.021) for all joints; T0 to T12 (p < 0.023) for MCF and knee; T0 to T24 (p < 0.019) only for MCF and knee. FlexG improved from T0 to T4 (p < 0.001) for all joints; T0 to T12 (p < 0.001) and T0 to T24 (p < 0.02) only for MCF and knee. ExtG improved from T0 to T4 (p < 0.001) for all joints except for elbow; T0 to T12 (p = 0.003) for wrist, metacarpophalangeal and knee; and T0 to T24 (p = 0.014) for MCF and knee. Conclusion: VASSw responded better at short and medium term after IAI with triamcinolone hexacetonide in our sample of RA patients.

Resumo Objetivos: Avaliar variáveis articulares locais após a injeção intra-articular (IIA) de hexacetonido de triancinolona (HT) em pacientes com artrite reumatoide (AR). Métodos: Avaliaram-se de modo cego e prospectivo (inicial, 1, 4, 12 e 24 semanas) as articulações metacarpofalângica (MCF), punho, cotovelo, ombro, joelho e tornozelo após a IIA de HT à procura das seguintes medidas de desfecho: escala visual analógica (EVA) de 0 a 10 cm para dor em repouso (EVAr); EVA para dor ao movimento (EVAm); EVA para inchaço das articulações (EVAi); flexão (FlexG) e extensão (ExtG). Resultados; Estudaram-se 289 pacientes (635 articulações). A EVAi (p < 0,001) e a EVAr (0,001 < p < 0,016) melhoraram de T0 a T4, T12 e T24 em todas as articulações. A EVAm melhorou de T0-T4 (p < 0,021) em todas as articulações; T0-T12 (p < 0,023) na MCF e no joelho; T0-T24 (p < 0,019) apenas na MCF e no joelho. A FlexG melhorou de T0-T4 (p < 0,001) em todas as articulações; T0-T12 (p < 0,001) e T0-T24 (p < 0,02) apenas na MCF e no joelho. A ExtG melhorou de T0-T4 (p < 0,001) em todas as articulações, exceto no cotovelo; T0-T12 (p = 0,003) no punho, na MCF e no joelho; e T0-T24 (p = 0,014) na MCF e no joelho. Conclusão: A EVAi respondeu melhor em curto e médio prazos após a IIA de HT na presente amostra de pacientes com AR.

Intra-articular injection with triamcinolone hexacetonide in patients with rheumatoid arthritis: prospective assessment of goniometry and joint inflammation parameters.

OBJECTIVES: To evaluate local joint variables after intra-articular injection with triamcinolone hexacetonide in rheumatoid arthritis patients. METHODS: We blindly and prospectively (baseline, 1, 4, 12 and 24 weeks) evaluated metacarpophalangeal, wrist, elbow, shoulder, knee and ankle joints after triamcinolone hexacetonide intra-articular injection by the following outcome measures: visual analogue scale 0-10cm (VAS) for rest pain (VASR); VAS for movement pain (VASM); VAS for joint swelling (VASSw); flexion (FlexG) and extension (ExtG). RESULTS: 289 patients (635 joints) were studied. VASSw (p<0.001) and VASR (0.001

Lipoatrofia por inyección de esteroides - Diagnóstico y tratamiento / Lipoatrophy by injection of steroids - Diagnosis and treatment

Existen diferentes opciones para el tratamiento de la lipoatrofi a secundaria a la inyección local de esteroides. Presentamos las diferentes alternativas de tratamiento y sus resultados sobre cuatro pacientes con diferente grado de lesión y en diferentes áreas corporales.

There are diff erent options for the treatment of lipoatrophy secondary to the local injection of steroids. We present the diff erent treatment alternatives and their results on four patients with diff erent degrees of injury and in diff erent body areas.

Solid-state characterization of triamcinolone acetonide nanosuspensiones by X-ray spectroscopy, ATR Fourier transforms infrared spectroscopy and differential scanning calorimetry analysis.

The data presented in this article describe the physical state of the triamcinolone acetonide (TA) in nanosuspension stabilized with polyvinyl alcohol (PVA) and poloxamer 407 (PL). The data were assessed by X-ray spectroscopy, ATR Fourier transforms infrared spectroscopy measurements (FTIR), and Differential scanning calorimetry (DSC) analysis. PVA, PL and polymeric mixture (PVA and PL) were compared with nanosuspension and the interactions between drug triamcinolone acetonide and polymers were studied. The data are related and are complementary to the research article entitle "Improved release of triamcinolone acetonide from medicated soft contact lenses loaded with drug nanosuspensions" (García-Millán et al., 2017) [1].

Characteristics of particulate and non-particulate corticosteroids. Indications for their use in chronic pain treatments. / Características de los corticoides particulados y no particulados. Condicionantes para su uso en el tratamiento del dolor crónico.

Corticosteroids been used frequently in pain treatments since the middle of last century (1952). Due to a review of the complications as a result of their application in epidural injections, the United States of America Food and Drug Administration (FDA) issued an «alert controversy¼ requesting that a warning label should be added to injectable corticosteroids, where risks must be described (loss of sight, brain damage, paralysis and death) when administering by this route. It must be mentioned that there are different types of corticosteroids with diverse characteristics, which as a result, may produce different side-effects. Due to the aforementioned developments, the controversies that have arisen, and the lack of well-conducted studies on the use of steroids in epidural injections, we must begin by reviewing their indications in different pain conditions.